SRC1 was the first cloned steroid receptor co-activator that interacts with steroid hormone receptors to promote transcriptional activation in a hormone-dependent manner.
The p160 SRC family contains three homologous members, SRC1, SRC2 and SRC3, that interact with nuclear receptors and specific transcription factors. They recruit chromatin remodelling and other transcriptional enzymes to facilitate the assembly of general transcription factors for transcriptional activation.
SRCs are post-translationally modified in response to several upstream signalling pathways. These post-translational modifications determine or modulate SRC stability, subcellular localization, functional specificity, co-activator activity and/or co-activator complex assembly or disassembly.
SRC-knockout mice show that SRCs are involved in many physiological processes and each SRC has both specific and redundant physiological functions in embryonic and adult tissues.
SRC1 expression is increased in a subset of breast cancers and is positively correlated with ERBB2 positivity and poor disease-free survival rate. Knockdown of SRC1 in breast cancer cells inhibits cell proliferation.
Knockout of Src1 in mouse mammary tumour virus (MMTV)–polyoma middle T (PyMT) mice suppresses metastasis without affecting primary tumour formation. SRC1 promotes breast cancer metastasis by upregulating ERBB2, colony stimulating factor 1 and TWIST1 expression.
Both gene amplification and overexpression of SRC3 occur in a subset of breast cancers. SRC3 overexpression usually correlates with the expression of ERBB2, matrix metalloproteinase 2 (MMP2), MMP9 and polyoma enhancer activator 3, and with larger tumour size, higher tumour grade and/or poor disease-free survival.
SRC3 has an important role in promoting breast tumour cell proliferation, migration, invasion and metastasis through many mechanisms, such as increasing the function of oestrogen receptor-α and E2F1, the activity of the insulin-like growth factor 1 (IGF1) signalling pathway, epidermal growth factor receptor (EGFR) and ERBB2, and the expression of MMPs.
Knockout of Src3 in mice suppresses mammary tumour initiation, growth and metastasis, and overexpression of SRC3 in mouse mammary epithelial cells is sufficient to induce spontaneous mammary tumorigenesis.
SRC3 expression is increased during prostate tumorigenesis in mice. Knockout of Src3 efficiently arrests prostate tumour progression at a well-differentiated stage.
The three homologous members of the p160 SRC family (SRC1, SRC2 and SRC3) mediate the transcriptional functions of nuclear receptors and other transcription factors, and are the most studied of all the transcriptional co-activators. Recent work has indicated that the SRCgenes are subject to amplification and overexpression in various human cancers. Some of the molecular mechanisms responsible for SRC overexpression, along with the mechanisms by which SRCs promote breast and prostate cancer cell proliferation and survival, have been identified, as have the specific contributions of individual SRC family members to spontaneous breast and prostate carcinogenesis in genetically manipulated mouse models. These studies have identified new challenges for cancer research and therapy.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Spelsberg, T. C., Steggles, A. W. & O'Malley, B. W. Progesterone-binding components of chick oviduct. 3. Chromatin acceptor sites. J. Biol. Chem. 246, 4188–4197 (1971).
O'Malley, B. W. Coregulators: from whence came these “master genes”. Mol. Endocrinol. 21, 1009–1013 (2007).
Meyer, M. E. et al. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57, 433–442 (1989).
Halachmi, S. et al. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264, 1455–1458 (1994).
Klein-Hitpass, L. et al. The progesterone receptor stimulates cell-free transcription by enhancing the formation of a stable preinitiation complex. Cell 60, 247–257 (1990).
Onate, S. A., Tsai, S. Y., Tsai, M. J. & O'Malley, B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270, 1354–1357 (1995). This article identified SRC1 as the first steroid receptor co-activator.
Voegel, J. J., Heine, M. J., Zechel, C., Chambon, P. & Gronemeyer, H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15, 3667–3675 (1996).
Hong, H., Kohli, K., Garabedian, M. J. & Stallcup, M. R. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol. 17, 2735–2744 (1997).
Torchia, J. et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387, 677–684 (1997).
Li, H., Gomes, P. J. & Chen, J. D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl Acad. Sci. USA 94, 8479–8484 (1997).
Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965–968 (1997). This article first reported that SRC3 was amplified and overexpressed in breast cancer.
Chen, H. et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90, 569–580 (1997).
Takeshita, A., Cardona, G. R., Koibuchi, N., Suen, C. S. & Chin, W. W. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J. Biol. Chem. 272, 27629–27634 (1997).
Chen, Y. H., Kim, J. H. & Stallcup, M. R. GAC63, a GRIP1-dependent nuclear receptor coactivator. Mol. Cell. Biol. 25, 5965–5972 (2005).
Kim, J. H., Li, H. & Stallcup, M. R. CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators. Mol. Cell 12, 1537–1549 (2003).
Lee, Y. H., Campbell, H. D. & Stallcup, M. R. Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity. Mol. Cell. Biol. 24, 2103–2117 (2004).
Belandia, B. & Parker, M. G. Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors. J. Biol. Chem. 275, 30801–30805 (2000).
Chen, S. L., Dowhan, D. H., Hosking, B. M. & Muscat, G. E. The steroid receptor coactivator, GRIP-1, is necessary for MEF-2C-dependent gene expression and skeletal muscle differentiation. Genes Dev. 14, 1209–1228 (2000).
Darimont, B. D. et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12, 3343–3356 (1998).
Heery, D. M., Kalkhoven, E., Hoare, S. & Parker, M. G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733–736 (1997).
Voegel, J. J. et al. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17, 507–519 (1998).
Anafi, M. et al. GCN5 and ADA adaptor proteins regulate triiodothyronine/GRIP1 and SRC-1 coactivator-dependent gene activation by the human thyroid hormone receptor. Mol. Endocrinol. 14, 718–732 (2000).
Brown, K., Chen, Y., Underhill, T. M., Mymryk, J. S. & Torchia, J. The coactivator p/CIP/SRC-3 facilitates retinoic acid receptor signaling via recruitment of GCN5. J. Biol. Chem. 278, 39402–39412 (2003).
Huang, S. M. & Stallcup, M. R. Mouse Zac1, a transcriptional coactivator and repressor for nuclear receptors. Mol. Cell. Biol. 20, 1855–1867 (2000).
Koh, S. S., Chen, D., Lee, Y. H. & Stallcup, M. R. Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J. Biol. Chem. 276, 1089–1098 (2001).
Liu, P. Y., Hsieh, T. Y., Chou, W. Y. & Huang, S. M. Modulation of glucocorticoid receptor-interacting protein 1 (GRIP1) transactivation and co-activation activities through its C-terminal repression and self-association domains. FEBSJ. 273, 2172–2183 (2006).
Ma, H. et al. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol. Cell. Biol. 19, 6164–6173 (1999).
Surapureddi, S. et al. Identification of a transcriptionally active peroxisome proliferator-activated receptor α-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc. Natl Acad. Sci. USA 99, 11836–11841 (2002).
Yao, T. P., Ku, G., Zhou, N., Scully, R. & Livingston, D. M. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc. Natl Acad. Sci. USA 93, 10626–10631 (1996).
Spencer, T. E. et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389, 194–198 (1997).
Xu, J. & Li, Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol. Endocrinol. 17, 1681–1692 (2003).
Zhang, H. et al. Differential gene regulation by the SRC family of coactivators. Genes Dev. 18, 1753–1765 (2004).
Jeong, J. W. et al. The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism. Mol. Endocrinol. 20, 1138–1152 (2006).
Oh, A. et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res. 64, 8299–8308 (2004).
Kamei, Y. et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403–414 (1996).
Kalkhoven, E., Valentine, J. E., Heery, D. M. & Parker, M. G. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 17, 232–243 (1998).
Reiter, R., Wellstein, A. & Riegel, A. T. An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J. Biol. Chem. 276, 39736–39741 (2001).
Lopez, G. N., Turck, C. W., Schaufele, F., Stallcup, M. R. & Kushner, P. J. Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J. Biol. Chem. 276, 22177–22182 (2001).
Rowan, B. G., Weigel, N. L. & O'Malley, B. W. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 275, 4475–4483 (2000).
Wu, R. C. et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol. Cell 15, 937–949 (2004).
Giamas, G. et al. CK1δ modulates the transcriptional activity of ERα via AIB1 in an estrogen-dependent manner and regulates ERα–AIB1 interactions. Nucleic Acids Res. 37, 3110–3123 (2009).
Ueda, T., Mawji, N. R., Bruchovsky, N. & Sadar, M. D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 277, 38087–38094 (2002).
Rowan, B. G., Garrison, N., Weigel, N. L. & O'Malley, B. W. 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol. Cell. Biol. 20, 8720–8730 (2000).
Gregory, C. W. et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem. 279, 7119–7130 (2004).
Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465–2468 (2002).
Shah, Y. M. & Rowan, B. G. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor-αpromoter interaction and elevated steroid receptor coactivator 1 activity. Mol. Endocrinol. 19, 732–748 (2005).
Frigo, D. E. et al. p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol. Endocrinol. 20, 971–983 (2006).
Borud, B. et al. The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1. Mol. Endocrinol. 16, 757–773 (2002).
Hoang, T. et al. cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. J. Biol. Chem. 279, 49120–49130 (2004).
Oh, A. S. et al. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol. Cell. Biol. 28, 6580–6593 (2008).
Bouras, T., Southey, M. C. & Venter, D. J. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 61, 903–907 (2001).
Osborne, C. K. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 95, 353–361 (2003).
Schiff, R., Massarweh, S., Shou, J. & Osborne, C. K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9, S447–S454 (2003).
Wu, R. C., Feng, Q., Lonard, D. M. & O'Malley, B. W. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 129, 1125–1140 (2007).
Li, C. et al. Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Mol. Cell 31, 835–849 (2008).
Yi, P. et al. Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol. Cell 29, 465–476 (2008).
Amazit, L. et al. Subcellular localization and mechanisms of nucleocytoplasmic trafficking of steroid receptor coactivator-1. J. Biol. Chem. 278, 32195–32203 (2003).
Hermanson, O., Glass, C. K. & Rosenfeld, M. G. Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol. Metab. 13, 55–60 (2002).
Qutob, M. S., Bhattacharjee, R. N., Pollari, E., Yee, S. P. & Torchia, J. Microtubule-dependent subcellular redistribution of the transcriptional coactivator p/CIP. Mol. Cell. Biol. 22, 6611–6626 (2002).
Amazit, L. et al. Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol. Cell. Biol. 27, 6913–6932 (2007).
Wu, R. C. et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by IκB kinase. Mol. Cell. Biol. 22, 3549–3561 (2002).
Zheng, F. F., Wu, R. C., Smith, C. L. & O'Malley, B. W. Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Mol. Cell. Biol. 25, 8273–8284 (2005).
Yu, C. et al. An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol. Cell 25, 765–778 (2007).
Baumann, C. T. et al. The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Mol. Endocrinol. 15, 485–500 (2001).
Shao, W., Keeton, E. K., McDonnell, D. P. & Brown, M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc. Natl Acad. Sci. USA 101, 11599–11604 (2004).
Yan, F., Gao, X., Lonard, D. M. & Nawaz, Z. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. Mol. Endocrinol. 17, 1315–1331 (2003).
Imhof, M. O. & McDonnell, D. P. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol. Cell. Biol. 16, 2594–2605 (1996).
Lonard, D. M., Nawaz, Z., Smith, C. L. & O'Malley, B. W. The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol. Cell 5, 939–948 (2000).
Gianni, M. et al. P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARα-mediated transcription. EMBO J. 25, 739–751 (2006).
Desterro, J. M., Rodriguez, M. S. & Hay, R. T. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol. Cell 2, 233–239 (1998).
Kirsh, O. et al. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 21, 2682–2691 (2002).
Chauchereau, A., Amazit, L., Quesne, M., Guiochon-Mantel, A. & Milgrom, E. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J. Biol. Chem. 278, 12335–12343 (2003).
Jimenez-Lara, A. M., Heine, M. J. & Gronemeyer, H. PIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2. FEBS Lett. 526, 142–146 (2002).
Kotaja, N., Vihinen, M., Palvimo, J. J. & Janne, O. A. Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling. J. Biol. Chem. 277, 17781–17788 (2002).
Kotaja, N., Karvonen, U., Janne, O. A. & Palvimo, J. J. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J. Biol. Chem. 277, 30283–30288 (2002).
Wu, H. et al. Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J. Biol. Chem. 281, 21848–21856 (2006).
Li, X. et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGγ proteasome. Cell 124, 381–392 (2006).
Chen, H., Lin, R. J., Xie, W., Wilpitz, D. & Evans, R. M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98, 675–686 (1999).
Feng, Q., Yi, P., Wong, J. & O'Malley, B. W. Signaling within a coactivator complex: methylation of SRC-3/AIB1 is a molecular switch for complex disassembly. Mol. Cell. Biol. 26, 7846–7857 (2006).
Naeem, H. et al. The activity and stability of the transcriptional coactivator p/CIP/SRC-3 are regulated by CARM1-dependent methylation. Mol. Cell. Biol. 27, 120–134 (2007).
Mark, M. et al. Partially redundant functions of SRC-1 and TIF2 in postnatal survival and male reproduction. Proc. Natl Acad. Sci. USA 101, 4453–4458 (2004).
Wang, Z. et al. Critical roles of the p160 transcriptional coactivators p/CIP and SRC-1 in energy balance. Cell. Metab. 3, 111–122 (2006).
Fleming, F. J., Hill, A. D., McDermott, E. W., O'Higgins, N. J. & Young, L. S. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by β-estradiol and 4-hydroxytamoxifen in human breast cancer. J. Clin. Endocrinol. Metab. 89, 375–383 (2004).
Fleming, F. J. et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J. Clin. Pathol. 57, 1069–1074 (2004). This article reported that SRC1 expression in breast cancer was correlated with ERBB2 positivity and worse DFS.
Myers, E. et al. Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br. J. Cancer 91, 1687–1693 (2004).
Hudelist, G. et al. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res. Treat. 78, 193–204 (2003).
List, H. J., Reiter, R., Singh, B., Wellstein, A. & Riegel, A. T. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res. Treat. 68, 21–28 (2001).
Qin, L. et al. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol. Cell. Biol. 28, 5937–5950 (2008).
Redmond, A. M. et al. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin. Cancer Res. 15, 2098–2106 (2009).
Tai, H., Kubota, N. & Kato, S. Involvement of nuclear receptor coactivator SRC-1 in estrogen-dependent cell growth of MCF-7 cells. Biochem. Biophys. Res. Commun. 267, 311–316 (2000).
Cavarretta, I. T. et al. Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERα transcriptional activity and MCF-7 proliferation. Mol. Endocrinol. 16, 253–270 (2002).
Wei, X., Xu, H. & Kufe, D. MUC1 oncoprotein stabilizes and activates estrogen receptor α. Mol. Cell 21, 295–305 (2006).
Kishimoto, H. et al. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1α/CXCL12. Carcinogenesis 26, 1706–1715 (2005).
Wang, S. et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc. Natl Acad. Sci. USA 106, 151–156 (2009). This article first reported that SRC1 deficiency strongly suppressed breast cancer metastasis in MMTV-PyMT mice by inhibiting ERBB2 and CSF1 expression.
Qin, L., Liu, Z., Chen, H. & Xu, J. The steroid receptor coactivator-1 (SRC-1) regulates Twist expression and promotes breast cancer metastasis. Cancer Res. 69, 3819–3827 (2009).
Girault, I. et al. Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin. Cancer Res. 9, 1259–1266 (2003).
Bautista, S. et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res. 4, 2925–2929 (1998).
Zhao, C. et al. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 98, 18–23 (2003).
Glaeser, M., Floetotto, T., Hanstein, B., Beckmann, M. W. & Niederacher, D. Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm. Metab. Res. 33, 121–126 (2001).
Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 20, 5041–5047 (2000).
Smith, C. L., Nawaz, Z. & O'Malley, B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11, 657–666 (1997).
Planas-Silva, M. D., Shang, Y., Donaher, J. L., Brown, M. & Weinberg, R. A. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res. 61, 3858–3862 (2001).
List, H. J. et al. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J. Biol. Chem. 276, 23763–23768 (2001).
Kuang, S. Q. et al. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res. 64, 1875–1885 (2004). This article first demonstrated that SRC3 deficiency suppressed oncogene-induced mammary tumour initiation, growth and metastasis and inhibited the IGF1 signalling pathways by downregulating IGF1, IRS1 and IRS2.
Kuang, S. Q. et al. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res. 65, 7993–8002 (2005). This article demonstrated that SRC3 deficiency specifically protected mouse mammary gland from chemical carcinogen-induced tumorigenesis.
Fereshteh, M. P. et al. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res. 68, 3697–3706 (2008).
Torres-Arzayus, M. I. et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6, 263–274 (2004). This article demonstrated that overexpression of SRC3 in mouse mammary epithelial cells caused spontaneous mammary tumors, suggesting that overexpressed SRC3 is oncogenic.
Maki, H. E. et al. Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate 66, 1391–1398 (2006).
Agoulnik, I. U. et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 65, 7959–7967 (2005).
Gregory, C. W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4315–4319 (2001).
Fujimoto, N., Mizokami, A., Harada, S. & Matsumoto, T. Different expression of androgen receptor coactivators in human prostate. Urology 58, 289–294 (2001).
Mori, R. et al. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res. 28, 425–430 (2008).
Tien, J. C.-Y., Zhou, S. & Xu, J. The role of SRC-1 in murine prostate carcinogenesis is nonessential due to a possible compensation of SRC-3/AIB1 overexpression. Int. J. Biol. Sci. 5, 256–264 (2009).
Agoulnik, I. U. et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 66, 10594–10602 (2006).
Gnanapragasam, V. J., Leung, H. Y., Pulimood, A. S., Neal, D. E. & Robson, C. N. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br. J. Cancer 85, 1928–1936 (2001).
Zhou, H. J. et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65, 7976–7983 (2005).
Zhou, G., Hashimoto, Y., Kwak, I., Tsai, S. Y. & Tsai, M. J. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol. Cell. Biol. 23, 7742–7755 (2003).
Chung, A. C. et al. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res. 67, 5965–5975 (2007). This article first reported that SRC3 deficiency in mice arrested spontaneous prostate cancer progression at a well-differentiated stage.
Xie, D. et al. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum. Pathol. 36, 777–783 (2005).
Kershah, S. M., Desouki, M. M., Koterba, K. L. & Rowan, B. G. Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecol. Oncol. 92, 304–313 (2004).
Uchikawa, J. et al. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer 98, 2207–2213 (2003).
Balmer, N. N. et al. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers. Mod. Pathol. 19, 1593–1605 (2006).
Xu, F. P. et al. SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas. Cancer Lett. 245, 69–74 (2007).
Sakakura, C. et al. Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int. J. Cancer 89, 217–223 (2000).
Yoshida, H. et al. Steroid receptor coactivator-3, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells. Mol. Cell. Endocrinol. 245, 77–85 (2005).
Henke, R. T. et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin. Cancer Res. 10, 6134–6142 (2004).
Carapeti, M., Aguiar, R. C., Goldman, J. M. & Cross, N. C. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91, 3127–3133 (1998).
Liang, J., Prouty, L., Williams, B. J., Dayton, M. A. & Blanchard, K. L. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood 92, 2118–2122 (1998).
Deguchi, K. et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 3, 259–271 (2003).
Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004).
Coste, A. et al. Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J. 25, 2453–2464 (2006).
Lahusen, T., Fereshteh, M., Oh, A., Wellstein, A. & Riegel, A. T. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res. 67, 7256–7265 (2007).
Yan, J. et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 68, 5460–5468 (2008).
Louie, M. C., Revenko, A. S., Zou, J. X., Yao, J. & Chen, H. W. Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol. Cell. Biol. 26, 3810–3823 (2006).
Louie, M. C., Zou, J. X., Rabinovich, A. & Chen, H. W. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol. Cell. Biol. 24, 5157–5171 (2004).
Mussi, P., Yu, C., O'Malley, B. W. & Xu, J. Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol. Endocrinol. 20, 3105–3119 (2006).
Mukherjee, A. et al. Steroid receptor coactivator 2 is critical for progesterone-dependent uterine function and mammary morphogenesis in the mouse. Mol. Cell. Biol. 26, 6571–6583 (2006).
Liu, Z., Liao, L., Zhou, S. & Xu, J. Generation and validation of a mouse line with a floxed SRC-3/AIB1 allele for conditional knockout. Int. J. Biol. Sci. 4, 202–207 (2008).
Xu, J. et al. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279, 1922–1925 (1998). This article first reported the phenotype of SRC1-knockout mice and demonstrated an important physiological role of the co-activator in vivo .
Weiss, R. E. et al. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J. 18, 1900–1904 (1999).
Kamiya, Y. et al. Modulation by steroid receptor coactivator-1 of target-tissue responsiveness in resistance to thyroid hormone. Endocrinology 144, 4144–4153 (2003).
Puigserver, P. et al. Activation of PPARγcoactivator-1 through transcription factor docking. Science 286, 1368–1371 (1999).
Picard, F. et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111, 931–941 (2002).
Gehin, M. et al. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol. Cell. Biol. 22, 5923–5937 (2002).
Ye, X. et al. Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. Proc. Natl Acad. Sci. USA 102, 9487–9492 (2005).
Chopra, A. R. et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 322, 1395–1399 (2008).
Xu, J. et al. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl Acad. Sci. USA 97, 6379–6384 (2000). This article first reported the phenotype of SRC3-knockout mice and demonstrated that SRC3 has an important role in growth and mammary gland development.
Wang, Z. et al. Regulation of somatic growth by the p160 coactivator p/CIP. Proc. Natl Acad. Sci. USA 97, 13549–13554 (2000).
Liao, L., Chen, X., Wang, S., Parlow, A. F. & Xu, J. Steroid receptor coactivator 3 maintains circulating insulin-like growth factor I (IGF-I) by controlling IGF-binding protein 3 expression. Mol. Cell. Biol. 28, 2460–2469 (2008).
Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758 (1997).
Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927–937 (1998).
Beischlag, T. V. et al. Recruitment of the NCoA/SRC-1/p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex. Mol. Cell. Biol. 22, 4319–4333 (2002).
Carlson, D. B. & Perdew, G. H. A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J. Biochem. Mol. Toxicol. 16, 317–325 (2002).
Kumar, M. B. & Perdew, G. H. Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. Gene Expr. 8, 273–286 (1999).
Lee, S. K. et al. Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J. Biol. Chem. 273, 16651–16654 (1998).
Dennis, J. H., Budhram-Mahadeo, V. & Latchman, D. S. Functional interaction between Brn-3a and Src-1 co-activates Brn-3a-mediated transactivation. Biochem. Biophys. Res. Commun. 294, 487–495 (2002).
Song, L. N. & Gelmann, E. P. Interaction of β-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J. Biol. Chem. 280, 37853–37867 (2005).
Goel, A. & Janknecht, R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J. Biol. Chem. 279, 14909–14916 (2004).
Martinez-Jimenez, C. P., Castell, J. V., Gomez-Lechon, M. J. & Jover, R. Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4α requires coactivators peroxisomal proliferator activated receptor-γ coactivator 1α and steroid receptor coactivator 1. Mol. Pharmacol. 70, 1681–1692 (2006).
Wang, J. C., Stafford, J. M. & Granner, D. K. SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4. J. Biol. Chem. 273, 30847–30850 (1998).
Reily, M. M., Pantoja, C., Hu, X., Chinenov, Y. & Rogatsky, I. The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J. 25, 108–117 (2006).
Gao, Z. et al. Coactivators and corepressors of NF-κB in IκB alpha gene promoter. J. Biol. Chem. 280, 21091–21098 (2005).
Li, G., Heaton, J. H. & Gelehrter, T. D. Role of steroid receptor coactivators in glucocorticoid and transforming growth factor βregulation of plasminogen activator inhibitor gene expression. Mol. Endocrinol. 20, 1025–1034 (2006).
Kino, T., Slobodskaya, O., Pavlakis, G. N. & Chrousos, G. P. Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex. J. Biol. Chem. 277, 2396–2405 (2002).
Yi, M., Tong, G. X., Murry, B. & Mendelson, C. R. Role of CBP/p300 and SRC-1 in transcriptional regulation of the pulmonary surfactant protein-A (SP-A) gene by thyroid transcription factor-1 (TTF-1). J. Biol. Chem. 277, 2997–3005 (2002).
Baldwin, A., Huh, K. W. & Munger, K. Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function. J. Virol. 80, 6669–6677 (2006).
Lee, S. K., Kim, H. J., Kim, J. W. & Lee, J. W. Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53. Mol. Endocrinol. 13, 1924–1933 (1999).
Batsche, E., Desroches, J., Bilodeau, S., Gauthier, Y. & Drouin, J. Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness. J. Biol. Chem. 280, 19746–19756 (2005).
Brosens, J. J., Hayashi, N. & White, J. O. Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells. Endocrinology 140, 4809–4820 (1999).
Mani, A. et al. E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells. Cancer Res. 66, 8680–8686 (2006).
Verma, S. et al. The ubiquitin-conjugating enzyme UBCH7 acts as a coactivator for steroid hormone receptors. Mol. Cell. Biol. 24, 8716–8726 (2004).
Zhang, A. et al. Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. J. Biol. Chem. 279, 33799–33805 (2004).
Lee, S. K. et al. A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J. Biol. Chem. 274, 34283–34293 (1999).
Chen, D. et al. Regulation of transcription by a protein methyltransferase. Science 284, 2174–2177 (1999).
Wu, X., Li, H. & Chen, J. D. The human homologue of the yeast DNA repair and TFIIH regulator MMS19 is an AF-1-specific coactivator of estrogen receptor. J. Biol. Chem. 276, 23962–23968 (2001).
Kino, T. & Chrousos, G. P. Tumor necrosis factor α receptor- and Fas-associated FLASH inhibit transcriptional activity of the glucocorticoid receptor by binding to and interfering with its interaction with p160 type nuclear receptor coactivators. J. Biol. Chem. 278, 3023–3029 (2003).
Kino, T., Ichijo, T. & Chrousos, G. P. FLASH interacts with p160 coactivator subtypes and differentially suppresses transcriptional activity of steroid hormone receptors. J. Steroid Biochem. Mol. Biol. 92, 357–363 (2004).
Liang, J., Zhang, H., Zhang, Y., Zhang, Y. & Shang, Y. GAS, a new glutamate-rich protein, interacts differentially with SRCs and is involved in oestrogen receptor function. EMBO Rep. 10, 51–57 (2009).
Chauchereau, A., Georgiakaki, M., Perrin-Wolff, M., Milgrom, E. & Loosfelt, H. JAB1 interacts with both the progesterone receptor and SRC-1. J. Biol. Chem. 275, 8540–8548 (2000).
Yi, P. et al. Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol. Cell. Biol. 25, 9687–9699 (2005).
Lanz, R. B. et al. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97, 17–27 (1999).
Berns, E. M., van Staveren, I. L., Klijn, J. G. & Foekens, J. A. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res. Treat. 48, 87–92 (1998).
Carroll, R. S. et al. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin. Cancer Res. 6, 3570–3575 (2000).
Hussein-Fikret, S. & Fuller, P. J. Expression of nuclear receptor coregulators in ovarian stromal and epithelial tumours. Mol. Cell. Endocrinol. 229, 149–160 (2005).
Lassmann, S. et al. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J. Mol. Med. 85, 293–304 (2007).
Fujita, Y. et al. Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology 50, 1857–1863 (2003).
Wang, Y. et al. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95, 2346–2352 (2002).
Chen, Y. J. et al. Genome-wide profiling of oral squamous cell carcinoma. J. Pathol. 204, 326–332 (2004).
Tanner, M. M. et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res. 6, 1833–1839 (2000).
This work was funded by US National Institutes of Health grants (R01DK058242, R01CA112403 and R01CA119689 to J.X.; P01DK059820, R01HD07857 and R01HD08818 to B.W.O.), National Institute of Diabetes and Digestive and Kidney Diseases-Nuclear Receptor Signalling Atlas, an American Cancer Society Research Scholar Award (ACS number RSG-05-082-01 to J.X.) and a Susan Komen for the Cure Award (BCTR0707225 to R.W.).
- pS2 gene
Agene that, in ERα-positive human breast cancer cells, such as MCF7 cells, is a direct target gene of ERα. On oestrogen treatment, pS2 mRNA expression can be substantially induced within 15 minutes.
- Pituitary isograft
Implantation of a pituitary gland isolated from a syngeneic donor mouse into the kidney capsule of a recipient mouse. On stimulation of the implanted pituitary isograft, the recipient mouse shows significantly increased levels of prolactin, progesterone and oestradiol.
About this article
Cite this article
Xu, J., Wu, RC. & O'Malley, B. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9, 615–630 (2009). https://doi.org/10.1038/nrc2695
A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells
Communications Biology (2021)
Chemical Science (2021)
Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches
Acta Pharmaceutica Sinica B (2021)